Symbol Lookup

Friday July 01, 2016 9:58 PM ET. Data delayed 15 minutes.
4.68
0.13 (2.86%)
Bid/Lots
4.67/0
Ask/Lots
4.69/0
Open/Prev Close
4.58/4.55
Day Range
4.57-4.72
52-Week Range
3.11-8.10
Vol/Avg Daily Vol
88.1K/59.9K
  • TSX Comp
  • TSX Venture
  • DJIA
  • S&P 500
  • NASDAQ
Price Comparison Chart
Data delayed at least 15 minutes.

Recent News»

1 New Today
Cytosorbents Secures $10 Mln Debt Facility from Bridge Bank
10 hours ago by MT Newswires
07:15 AM EDT, 07/01/2016 (MT Newswires) -- Cytosorbents (CTSO), an immunotherapy company, said Friday that ti has closed a $10 million senior debt facility with the Life Sciences Group of Bridge Bank, a division of Western Alliance Bank (WAL). Th...
CytoSorbents Closes $10 Million Debt Financing with Bridge Bank
10 hours ago by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb(R) blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery ...

Cytosorbents Awarded $150,000 U.S. Army Contract for Universal Plasma Development
9:15AM ET on Wednesday Jun 22, 2016 by MT Newswires
09:15 AM EDT, 06/22/2016 (MT Newswires) -- Immunotherapy company Cytosorbents (CTSO) has been awarded a $150,000 Phase I Small Business Technology Transfer (STTR) contract from the U.S. Army to develop blood purification technologies that may ena...
CytoSorbents Awarded $150,000 Phase I STTR Contract for Universal Plasma Development
9:00AM ET on Wednesday Jun 22, 2016 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy specializing in blood purification, announced that it was awarded a $150,000 Phase I Small Business Technology Transfer (STTR) contract to develop blood purificati...

Cytosorbents Reports Sales Effort For CytoSorb In Europe
8:39AM ET on Wednesday Jun 01, 2016 by MT Newswires
08:39 AM EDT, 06/01/2016 (MT Newswires) -- Cytosorbents (CTSO), an immunotherapy developer, reported that strategic partner Fresenius Medical Care (FMS) is initiating sales efforts for its flagship product, the CytoSorb blood purification cartrid...

Company Information

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

CONTACT INFORMATION

Headquarters7 Deerpark Dr Ste K
MONMOUTH JUNCTION, NJ, United States 08852-1921
Phone973-329-8885
Fax732-329-8650

EXECUTIVE OFFICERS

Chairman of the BoardAl Kraus
President, Chief Executive Officer, DirectorPhillip Chan
Chief Financial OfficerKathleen Bloch
Chief Operating OfficerVincent Capponi
Chief Medical OfficerRobert Bartlett

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Stocks Ratings Sample

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

  •  
  • INK Company Insider

    Detailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®

  • S&P Capital IQ Stock Report

    S&P Capital IQ's analysts' overview and valuation, with key fundamental, quantitative, and technical analysis.

  • TDSI Morning Action Notes

    Morning Institutional Report of company updates and new recommendations.

Market Cap$115.6MBeta-0.03
Revenue (TTM)$5.9MEPS$-0.22
Shares Out.25.4MBook Value$0.32
Dividend Yield0.00%P/E--
Annual Dividend Rate0.00 USDPrice/Sales (TTM)19.7
Ex-Div Date1/1/01P/Cash Flow (TTM)--
Pay Date1/1/01Operating Margin-155.32%

*GAAP = prior to non-GAAP analyst adjusted earnings.

(Non-GAAP)*

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Stocks Calendar Sample